Metabolic Syndrome Prevalence among Prediabetic and Normoglucotolerant Women

Damaris Enyegue Mandob¹*, Pegba Sabine¹

¹Department of Biological Sciences, Higher Teachers’ Training College, University of Yaoundé I, P.O. Box 047, Yaoundé, Cameroon

*Correspondence author: Mandob Enyegue Damaris, Department of Biological Sciences, Higher Teachers’ Training College, University of Yaoundé I, Po Box 047, Yaoundé, Cameroon. Tel: +237699909163; E-mail: damaris.mandob@yahoo.fr

Received date: Sep 20, 2016; Accepted date: Oct 03, 2016; Published date: Oct 08, 2016

Abstract

Prediabetes is a known risk factor for type 2 diabetes and lead to long term complications such as cardiovascular diseases. In Cameroon, they are limited data dealing with prediabetes prevalence among Cameroonians. Our study objective was to estimate the prevalence of metabolic syndrome among prediabetic women and normoglyceamic women.

Methods: A total of 200 women (100 prediabetic women and 100 normoglyceamic) participated in the study, they were aged between 20-55 years. For their studied data, they were referred to the Andre Fouda Medical Foundation in Yaounde. Metabolic syndrome was diagnosed using Adult Treatment Panel-III [ATP-III] 2001 guidelines and prediabetes was defined as impaired fasting plasma glucose ranged between 6.1-6.9 mmol/l.

Results: The frequency of various cardiovascular risk factors was not different among the two group of study; only fasting blood glucose was significantly high among prediabetes compared to normoglyceamic women. The mean age in prediabetic women was 34.34 ± 8.96 years and 35.48 ± 9.88 years among normoglyceamic women. Among the prediabetic population, a total 61% of patients had hyperglycaemia, 59% had hypertension, 58% had increased waist circumference and 56% were diagnosed with metabolic syndrome. The most common abnormalities in normoglyceamic women was hypertension (58%), increased waist circumference (53%) and low HDL (52%). The metabolic syndrome was diagnosed in 23% of normoglyceamic women. Prediabetes women had a relative high risk of metabolic syndrome 2.43 compared to normoglyceamic women.

Conclusion: This study shows that prediabetes is associated with increased prevalence of metabolic syndrome among Cameroonian women. Lifestyle interventions and medication should be instituted to avoid complications among prediabetics.

Keywords: Metabolic syndrome; Prediabetes; Normoglyceamic; Women; Cameroon

Introduction

Prediabetes is a condition where blood glucose concentration is higher than normal but, not enough to be call type 2 diabetes, it is the borderline of type 2 diabetes [1]. Sometimes, people who develop type 2 diabetes develops firstly prediabetes, but not everyone who has prediabetes ends up with diabetes [2]. In fact, changing lifestyle can significantly delay or even prevent type 2 diabetes [3,4], however for American Diabetes Association (ADA), it is a clear need for most people to check their blood sugar [glucose] levels regularly and avoid complications. Prediabetes has no signs and symptoms, people with prediabetes have a greater risk of developing type 2 diabetes and/or associated complications [5-8]. Prediabetes generally aggregates with other cardiovascular risk factors and make up metabolic syndrome. Metabolic syndrome is an assemblage of risk factors that increases the risk of cardiovascular disease and type 2 diabetes. These factors include dysglycemia, high blood pressure, elevated triglyceride levels, low high-density lipoprotein cholesterol levels [HDL-C], and obesity [9,10]. With high rate of nutritional transition in developing countries, metabolic syndrome [11] and diabetes [12,13] prevalence is increasingly common and both diseases are important public health problem. Glucose abnormality can be present [14] or not in metabolic syndrome [15,16]. In Cameroon, there are limited published data dealing with glucose abnormalities and metabolic syndrome. This study compared the frequency and risk of metabolic syndrome between prediabetic and normoglucooler tolerant women.

Materials and Methods

Ethics

The cross sectional study was approved by the Education Planning Commission of Fouda Medical Foundation. Women were recruited through free multiple chronic diseases campaign from March 2014 to March 2016. Admission to the study was based solely on voluntary participation of women. The study volunteers were therefore referred at the Medical Foundation Andre Marie Fouda, Yaounde Cameroon. Exclusion from the study occur if women were not taking any medications that can affect blood glucose or having history of endocrine disorder like diabetes or thyroid diseases. At the time of recruitment all the participants were explained and provided a detail information leaflet about study objectives, procedures and the risk and benefits involved. All the participants were instructed to maintain fast
of at least 12 hours till blood collection. The participants were reassured about the confidentiality of data. Females were excluded from the study if they were pregnant or lactating. All participants in the study provided verbal informed consent. All measurements and questionnaire were in accordance with the Helsinki Declaration (1983 version).

**Subjects**

The data collection comprised healthcare questionnaire, anthropometric measurement of weight, Height, and abdominal circumference, health examination and laboratory test in fasting state for lipids and fasting blood glyceamia.

Height, weight, and waist circumference were all measured using standardized techniques and calibrated equipment. BMI was calculated by dividing weight by height squared [kg/m$^2$] classified according to WHO rules ≥ 30 [17].

A well trained nurse drew 10 ml of fasting morning blood samples from the examinees arm. Two ml was dispensed into fluoride oxalate tubes and the rest into vacutainer plain for separation of plasma and serum respectively. Standardized techniques were used to obtain the blood pressure measurements after at least 10 min of rest.

Waist circumference was taken with the subject in a standing position, to the nearest millimetre, using a non-stretchable tape measure at the mid-point between the lowest rib and the iliac crest in expiration. The height was measured in standing position using tape meter while the shoulder was in a normal position to the nearest millimetre [Siber Hegner, Zurich, Switzerland]. Body weight and body fat were determined in 12 h fasted participants [with very light clothing on and without shoes] using a “Tanita” scale. Glucose was assayed in the plasma by the glucose oxidase peroxidase colorimetric enzymatic method while serum was used for lipid profile. Total cholesterol and triglycerides in plasma were measured using previously described standard methods [18,19]. High Density Lipoprotein cholesterol was determined using a heparin manganese precipitation of Apo B-containing lipoproteins [20].

**Definition of Metabolic Syndrome**

Workers were considered to have Metabolic Syndrome if they had three or more of the following criteria, according to the ATPIII definition [21].

1. Abdominal obesity, defined as a waist circumference in women ≥ 88 cm [35 inches], in men ≥ 102 cm [40 inches].
2. Hypertriglyceridemia ≥ 150 mg/dL [1.7mmol/L] or drug treatment for elevated triglycerides.
3. HDL cholesterol level <50 mg/dL [1.3 mmol/L] in women, <40 mg/dL [1mmol/L] in men or drug treatment for low HDL-C.
4. Blood pressure ≥ 130/85 mmHg or drug treatment for elevated blood pressure
5. Fasting plasma glucose [FPG] ≥ 110 mg/dL [6.1mmol/L] or drug treatment for elevated blood glucose [22].

**Definition of Prediabetes**

The diagnostic of prediabetes was made with IFG [Impaired fasting Glucose levels belonging to the range of 100 to 125mg/dL after an overnight fast [1].

**Statistical analysis**

All data were analyzed by STATA® 8.2. Continuous variables are reported as means ± standard deviations [SD] and categorical variables are presented as percentages or numbers. A p value less than 0.05 was considered statistically significant. Quantitative and qualitative variables were tested using Student’s t-test and the chi-square test respectively. P value <0.05 was considered statistically significant.

**Results**

Of a total of 603 women screened through fasting plasma glucose during the campaign, based on the results of above test, women were classified according to ADA, the first 100 prediabetics and first100 normoglyceamic were selected for our study. The mean age was 35.48 ± 9.88 for normoglyceamic women and 34.34 ± 8.96 for prediabetic women respectively. The prevalence of individuals components of metabolic syndrome among prediabetic were shown to be: high fasting glucose levels 61%, high waist circumference 59%, high blood pressure 58%, low high density lipoprotein-cholesterol 56% and triglyceride levels 10 %. Among normoglyceamic high blood pressure was reported among 58%, high waist circumference among 53%, low high density lipoprotein-cholesterol among 52% and triglyceride levels 14%.

Prediabetic women with metabolic syndrome represented 48% with 3 abnormalities 6 with abnormalities and 2 with five metabolic abnormalities. Among normoglyceamic individuals, with metabolic syndrome represented 22% with 3 abnormalities, 1 with abnormalities, and nobody with five metabolic abnormalities.

Prevalence rates of metabolic syndrome varied according to hyperglycaemia status, 56% of prediabetic women had metabolic syndrome while 23% of normoglyceamic women had metabolic syndrome. Prediabetic women had a relative risk of 2.43 (Tables 1-4).

**Discussion**

Worldwide, the World Health Organization estimates that 346 million have type 2 diabetes mellitus [23]. Diabetes is the four leading cause of mortality among developing countries. In Cameroon there is an urban rural discrepancy among diabetes prevalence and 60% of diabetes cases are undiagnosed. The major and long term complications of diabetes are cardiovascular diseases that lead to many complications. It is important to identify individuals at early stages of type 2 diabetes for efficient [24]. Prediabetes is the intermediary state between normal glycaemia and diabetes, at this stage this condition is reversible if early detected and appropriate measure taken [25]. The conversion rate of hyperglycemia to metabolic abnormalities depends on degree of initial glycaemia, ethnic background, and environmental influence. The higher the glucose values, greater the risk of progression to diabetes and others complications of prediabetes [19].

Ciccone et al. [26] study show that Prediabetic condition is a further expression of incipient atherosclerosis lesions development through synergism between systemic inflammatory condition and the presence of high blood glucose concentrations. The enhanced oxidative stress generated, the increased circulating free fatty acids and the altered lipids metabolism induce heart structure damages that can lead to diabetic cardiomyopathy.
### Table 1: Demographic and clinical characteristics of Total, Prediabetics and normoglycemic Women.

| Parameters          | Total | Normoglycemic Women | Prediabetic Women | P value |
|---------------------|-------|---------------------|-------------------|---------|
| All women, No. [%]  | 200   | 100                 | 100               | -       |
| Age [years]         | 34.86 ± 9.40 | 35.48 ± 9.88 | 34.34 ± 8.96 | 0.582   |
| BMI, kg/m²          | 30.80 ± 5.98 | 30.42 ± 4.99 | 31.17 ± 6.39 | 0.317   |
| WC, cm              | 102.02 ± 12.21 | 101.08 ± 11.42 | 102.98 ± 12.21 | 0.39    |
| SBP, mmHg           | 129.15 ± 23.78 | 127.66 ± 20.53 | 130.68 ± 26.81 | 0.481   |
| DBP, mmHg           | 86.21 ± 14.50 | 85.47 ± 14.72 | 87.00 ± 14.35 | 0.562   |
| FBS, mg/dl          | 95.96 ± 19.22 | 79.42 ± 11.17 | 112.50 ± 8.02 | 0.000*  |
| TG, mg/dl           | 86.74 ± 13.16 | 80.80 ± 14.57 | 92.68 ± 15.91 | 0.226   |
| T-Chol, mg/dl       | 146.84 ± 53.64 | 151.77 ± 56.63 | 142.18 ± 50.73 | 0.353   |
| HDL-Chol, mg/dl     | 57.66 ± 40.73 | 57.04 ± 42.33 | 58.25 ± 39.49 | 0.871   |

*Significant difference between subject with prediabetic and normoglycemic women BMI: Body Mass Index; WC: Waist Circumference; SBP: Systolic Blood Pressure; DBP: Diastolic Blood Pressure; FBS: Fasting Blood Glucose; TG: Triglyceride; T-CHOL: Total Cholesterol and HDL-CHOL: HDL-cholesterol *P value less than 0.05 was considered significant.

### Table 2: Prevalence of Metabolic Syndrome individual components.

| Individual components | Normoglycemic Women | Prediabetic Women | P-Value |
|-----------------------|---------------------|-------------------|---------|
| Hyperglycaemia        | 0                   | 61                | 0       |
| Low HDL               | 52                  | 56                | 0.821   |
| High Triglycerides    | 14                  | 10                | 0.342   |
| Abdominal obesity     | 53                  | 58                | 0.353   |
| Hypertension          | 58                  | 59                | 0.746   |

*P<0.05 considered significant

### Table 3: Metabolic Syndrome Items.

There are scarce studies dealing with comparison of metabolic syndrome among prediabetics and normoglycemics individuals in Cameroon, this is the first report on metabolic syndrome and prediabetes. Based on NCEP definition, the overall prevalence of metabolic syndrome among prediabetic women was 56% and 23% among normoglycemic women. The prevalence of metabolic syndrome of our study is higher than the one reported among prediabetics Pakistan report [27]. The difference between the two studies can be explained by the size of study population (100 for our study verse 40 for the Pakistan study), the methods of prediabetes diagnosis (impaired fasting glucose for our study and for the Pakistan study two method oral glucose tolerance test and impaired fasting glucose) and the nutritional status of our population [our study population was obese while the Pakistan study population was only overweight.

| Parameters         | Normoglycemic Women | Prediabetic Women | P-Value |
|--------------------|---------------------|-------------------|---------|
| 3 criteria n [%]   | 22                  | 48                | 0.000   |
| 4 criteria n [%]   | 1                   | 6                 | 0.000   |
| 5 criteria n [%]   | 0                   | 2                 | 0.154   |

### Table 4: Distribution of Metabolic Syndrome in Normoglycemic and Prediabetic women.

Prediabetic women had a relative risk of metabolic syndrome of 2.43, this risk is higher than the relative risk of 1.27 to develop cardiovascular diseases recorded from Levitan et al. in the meta-analysis where pre-diabetic condition increases the cardiovascular risk profile of individuals [28]. The conversion of hyperglycaemia to it associated complications is enhanced with risk factors such as obesity, being overweight or obese is the main modifiable risk factor for type 2 diabetes, as body mass index increases, so does the risk of type 2 diabetes. In addition, duration of obesity has also been found to increase risk of developing type 2 diabetes, with greater risk among people who have been obese for longer periods of time [14]. In our study, while comparing individual metabolic syndrome risk factor, only a significant difference of altered fasting plasma glucose was found among prediabetic and normoglycemic women, this is not in agreement with Pakistan study [27] where a higher frequency of all individual components of cardiovascular risk factors was found. Among prediabetic obese youth, Shah et al. [29] study show has that demonstrated that there is an increased common carotid intima-media thickness (an important marker of atherosclerosis) comparatively to...
obese youth with normal glyceamic control. Also it is noted that prediabetes altered the performance of coronary vessels which increases the overall cardiovascular risk of individuals.

It is well known that most of people suffering from prediabetes often reveal insulin-resistance and the resulting chronic hyperglycemia further at lesser extent advances pancreatic β-cell dysfunction [30,31]. Glucose toxicity occurs through several mechanisms that begin when hyperglycemia leads to an increase in the intracellular glucose level. The damaging effects of elevated intracellular glucose levels may stem from alterations in a number of pathways [32-38]; oxidative stress and reactive oxygen species creation.

Hyperglycemia, in fact is able to activate protein kinase C which is able to enhance nicotinamide adenine dinucleotide phosphate [NADP] oxidase action, thus promoting the genesis of reactive oxygen species [ROS] and consequently, oxidative stress [18,19]. The same happens after the production of the advanced glycation end [AGE] products which are compound able to increase NADP oxidase activity, ROS generation and enhance coagulation processes. Moreover hyperglycemia is able to increase the flux through the hexosamine pathway and to induce the polyol pathway; all conditions related to a further ROS generation and finally to induce over-expression of growth factors and inflammatory cytokines [16,17].

Furthermore, beyond oxidative stress, hyperglycemia is able to impair and uncouple endothelial nitric oxide [eNOS] activity [16]. Such an impairment is dangerous because predisposes to endothelial dysfunction, which is a well know early marker of atherosclerosis and increased cardiovascular risk [20,21]. Strengths of our study are the use of standardized data collection of protocol as well as a relatively large size of prediabetes women. Although metabolic syndrome studies in Cameroon are arising, this study is the first study evaluating metabolic syndrome among prediabetic women.

The main limitations of this study were its cross sectional nature and Prediabetes was not diagnostic through oral glucose tolerance or glycated hemoglobin test.

Conclusion

This study shows that metabolic syndrome prevalence is higher among prediabetic women comparatively to normoglycemic ones. Although costly, it important to organized early screening for prediabetes among women for reducing the prevalence of type 2 diabetes. Prediabetes risk factors should be studied among our population for prevention and treatment of prediabetic patients.

Acknowledgements

The authors thank all the participants of the study as well as the medical foundation personnel.

References

1. American Diabetes LLK LK Association. Diagnosis and classification of diabetes mellitus Diabetes Care 35:S64-71.
2. Tabak AG, Herder C, Rathmann W, Brunner EJ, Kivimaki M (2012) Prediabetes: a high-risk state for diabetes development. Lancet 379: 2279-2290.
3. Perreault L, Pan Q, Mather KJ, Watson KE, Hamman RF, et al. (2012) Effect of regression from prediabetes to normal glucose regulation on long-term reduction in diabetes risk: results from the Diabetes Prevention Program Outcomes Study. Lancet 379: 2243-2251.
4. Schellenberg ES, Dryden DM, Vandermeer B, Ha C, Korownyk C (2013) Lifestyle interventions for patients with and at risk for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med 159: 543-551.
5. Ford ES, Zhao G, Li C (2010) Pre-diabetes and the risk for cardiovascular disease: a systematic review of the evidence. J Am Coll Cardiol 55: 1310-1317.
6. Cheng YJ, Gregg EW, Geiss LS, Imperatore G, Williams DE, et al. (2009) Association of A1C and fasting plasma glucose levels with diabetic retinopathy prevalence in the US population implications for diabetes diagnostic thresholds. Diabetes Care 32: 2027-2032.
7. Nathan DM, Chew E, Christophi CA, Davis MD, Fowler S, et al. (2007) The prevalence of retinopathy in impaired glucose tolerance and recent-onset diabetes in the Diabetes Prevention Program. Diabetic Med 24: 137-44.
8. Ziegler D, Rathmann W, Dickhaus T, Meisinger C, Mielck A; KORA Study Group (2008) Prevalence of polyneuropathy in pre-diabetes and diabetes is associated with abdominal obesity and macroangiopathy: the MONICA/KORA Augsburg Surveys S2 and S3. Diabetes Care 31: 464-469.
9. Grundy SM, Cleeman JL, Daniels SR, Donato KA, Eckel RH, et al. (2005) Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Circulation 112: 2735-2752.
10. Wilson PW, D’Agostino RB, Parise H, Sullivan L, Meigs JB (2005) Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation 112: 3066-3072.
11. Basit A, Shera AS (2008) Prevalence of metabolic syndrome in Pakistan. Metab Syndr Relat Disord 6: 171-175.
12. de-Graft Aikins A, Unwin N, Ayegamie C, Allopety P, Campbell C, et al. (2010) Tackling Africa’s chronic disease burden: from the local to the global. Global Health 6: 5.
13. Lekoubou A, Awah P, Fezeu L, Sobngwi E, Kengne AP (2010) Hypertension, diabetes mellitus and task shifting in their management in sub-Saharan Africa. Int J Environ Res Public Health 7: 353-363.
14. Grundy SM (2012) Pre-diabetes, metabolic syndrome, and cardiovascular risk. J Am Coll Cardiol 59: 635-643.
15. Eschwege E, Richard JL, Tibiult N, Ducimetiere P, Warner JM (1985) Coronary heart disease mortality in relation with diabetes, blood glucose and plasma insulin levels: the Paris Prospective Study, ten years later. Horm Metab Res 15: 41-46.
16. Beckman JA, Creager MA, Libby P (2005) Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA 298: 2570-2581.
17. Obesity (2008) preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser 894: 1-253.
18. Frank CC, Poon LS, Chan CS, Richmond W, Fu PC (1974) Enzymatic determination of total serum cholesterol. Clin Chem 20: 470-475.
19. Bucolo G, David H (1973) Quantitative determination of serum triglycerides by the use of enzymes. Clin Chem 19: 476-482.
20. Warnick GR, Albers JJ (1978) Heparin–Mn2+ quantitation of high-density-lipoprotein cholesterol: an ultrafiltration procedure for lipemic samples. Clin Chem 24: 900-904.
21. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (2001) Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III), JAMA 285: 2486-2497.
22. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (1997) Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 20: 1183-1197.
23. World Health Organization (2011) WHO. Diabetes Fact Sheet 212.
24. American Diabetes Association (2011) Standards of medical care in diabetes—2011. Diabetes Care 34: S11-S61.
25. Brown A, Reynolds LR, Bruegger D (2010) Intensive glycemic control and cardiovascular disease: an update. Nat Rev Cardiol 7: 369-375.
26. Ciccone MM, Scicchitano P, Cameli M, Cecere A, Cortese F, et al. (2014) Endothelial Function in Pre-diabetes, Diabetes and Diabetic Cardiomyopathy: A Review. J Diabetes Metab 5: 364.

27. Ahsan S, Ahmed SD, Jamali SN, Imran M, Haque MS, et al. (2015) Frequency and risk of metabolic syndrome in prediabetics versus normal glucose tolerant subjects -- a comparative study. J Pak Med Assoc 65: 496-500.

28. Levitan EB, Song Y, Ford ES, Liu S (2004) Is nondiabetic hyperglycemia a risk factor for cardiovascular disease? A meta-analysis of prospective studies. Arch Intern Med 164: 2147-2155.

29. Shah AS, Gao Z, Urbina EM, Kimball TR, Dolan LM (2014) Prediabetes: the effects on arterial thickness and stiffness in obese youth. J Clin Endocrinol Metab 99: 1037-1043.

30. Guillausseau PJ, Meas T, Virally M, Laloï-Michelin M, Médeau V, et al. (2008) Abnormalities in insulin secretion in type 2 diabetes mellitus. Diabetes Metab 34 Suppl 2: S43-48.

31. Poitout V, Hagman D, Stein R, Artner I, Robertson RP, et al. (2006) Regulation of the insulin gene by glucose and fatty acids. J Nutr 136: 873-876.

32. Brownlee M (2005) The pathobiology of diabetic complications: a unifying mechanism. Diabetes 54: 1615-1625.

33. Kawahito S, Kitahata H, Oshita S (2009) Problems associated with glucose toxicity: role of hyperglycemia-induced oxidative stress. World J Gastroenterol 15: 4137-4142.

34. Di Mario U, Pugliese G (2001) 15th Golgi lecture: from hyperglycaemia to the dysregulation of vascular remodelling in diabetes. Diabetologia 44: 674-692.

35. Creager MA, Luscher TF, Cosentino F, Beckman JA (2003) Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: Part I. Circulation 108: 1527-1532.

36. van den Oever IA, Raterman HG, Nurmohamed MT, Simsek S (2010) Endothelial dysfunction, inflammation, and apoptosis in diabetes mellitus. Mediators Inflam 792393.

37. Beisswenger PJ, Howell SK, Nelson RG, Mauer M, Szwergold BS (2003) Alpha-oxoaldehyde metabolism and diabetic complications. Biochem Soc Trans 31: 1358-1363.

38. Ceriello A, Ihnat MA, Thorpe JE (2009) Clinical review 2: the "metabolic memory": is more than just tight glucose control necessary to prevent diabetic complications? J Clin Endocrinol Metab 94: 410-415.